Table 3. Comparison 1: amantadine versus placebo: urine toxicology (cocaine metabolite).
Study | Outcome (see note 1) | Experimental group (n=8 randomised) (n=3 completed) | Control group (n=4 randomised) (n=3 completed) | Statistic |
---|---|---|---|---|
Leal 1994 | % cocaine-free urine samples: during first 2 weeks | 6% | 0% | none available (see note 2) |
Leal 1994 | % cocaine-free urine samples: during weeks 5 & 6 | 6% | 25% | none available (see note 2) |
Leal 1994 | % cocaine-free urine samples: during last 2 weeks | 0% | 0% | none available (see note 2) |
1. urinalyses performed twice-weekly throughout study and evaluated for cocaine metabolite (benzoylcognine).
2. trial investigators report no statistical analysis that compares experimental and control groups; however they note that “when comparing the first and last two weeks of treatment … AsPD … patients treated with placebo showed no difference in the percentage of cocaine-free urines … medicated AsPD patients [those receiving either amantadine 300 mg/day or desipramine 150 mg/day; total n=15] also showed no change in cocaine-free urines (13% to 14%)” (page 33, col 2).